Rhinology:局部过敏性鼻炎的患病率和特征分析

2019-01-01 AlexYang MedSci原创

局部过敏性鼻炎(LAR)在一些患者中发现具有典型的症状,但是那些对气源性致敏原具有阴性皮刺试验和阴性lgE的患者却表现出了对一定过敏原阳性鼻腔激发试验结果。到目前为止,对LAR的患病率和临床特征仍旧了解很少。最近,有研究人员确定了具有慢性鼻炎LAR患者的流行度和特征情况。研究包括了680名年龄不小于5岁的患者,分布于波兰的17个地点。研究总共调查了621名患者。LAR在109(17.6%)名患者中

局部过敏性鼻炎(LAR)在一些患者中发现具有典型的症状,但是那些对气源性致敏原具有阴性皮刺试验和阴性lgE的患者却表现出了对一定过敏原阳性鼻腔激发试验结果。到目前为止,对LAR的患病率和临床特征仍旧了解很少。最近,有研究人员确定了具有慢性鼻炎LAR患者的流行度和特征情况。

研究包括了680名年龄不小于5岁的患者,分布于波兰的17个地点。研究总共调查了621名患者。LAR在109(17.6%)名患者中诊断;AR在251(40.4%)名患者中诊断;NAR在261(42%)名患者中诊断。在LAR组中,那些年龄更小、不抽烟且对蕨类植物或者草花粉过敏的患者比较突出。多重致敏在AR患者中要比LAR患者更加流行。支气管哮喘在AR患者(38%)和LAR(35%)患者中的诊断率相似,但是在诊断为NAR(16%)的患者患病率显著更低。另外,疾病起始的平均年龄在AR和LAR患者中相似(17.6±4.8岁),并且在NAR患者显著更低(24.5±6.9岁,p<0.05)。

最后,研究人员指出,LAR在具有慢性鼻症状的各种年龄段的患者中研究不是很多。患有LAR和AR的患者具有相似的临床表型。

原始出处:

Bozek A, Scierski W, Ignasiak B et al. The prevalence and characteristics of local allergic rhinitis in Poland. Rhinology. 17 Dec 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027800, encodeId=6531202e80082, content=<a href='/topic/show?id=72784e6449c' target=_blank style='color:#2F92EE;'>#局部过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47644, encryptionId=72784e6449c, topicName=局部过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Dec 17 14:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047060, encodeId=c2a9204e06031, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 18 08:21:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250594, encodeId=9f241250594b5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405883, encodeId=cdb5140588398, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356914, encodeId=4d863569144f, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Jan 01 15:53:07 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027800, encodeId=6531202e80082, content=<a href='/topic/show?id=72784e6449c' target=_blank style='color:#2F92EE;'>#局部过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47644, encryptionId=72784e6449c, topicName=局部过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Dec 17 14:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047060, encodeId=c2a9204e06031, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 18 08:21:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250594, encodeId=9f241250594b5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405883, encodeId=cdb5140588398, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356914, encodeId=4d863569144f, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Jan 01 15:53:07 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2027800, encodeId=6531202e80082, content=<a href='/topic/show?id=72784e6449c' target=_blank style='color:#2F92EE;'>#局部过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47644, encryptionId=72784e6449c, topicName=局部过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Dec 17 14:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047060, encodeId=c2a9204e06031, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 18 08:21:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250594, encodeId=9f241250594b5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405883, encodeId=cdb5140588398, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356914, encodeId=4d863569144f, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Jan 01 15:53:07 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2027800, encodeId=6531202e80082, content=<a href='/topic/show?id=72784e6449c' target=_blank style='color:#2F92EE;'>#局部过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47644, encryptionId=72784e6449c, topicName=局部过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Dec 17 14:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047060, encodeId=c2a9204e06031, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 18 08:21:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250594, encodeId=9f241250594b5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405883, encodeId=cdb5140588398, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356914, encodeId=4d863569144f, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Jan 01 15:53:07 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2019-01-03 chg122
  5. [GetPortalCommentsPageByObjectIdResponse(id=2027800, encodeId=6531202e80082, content=<a href='/topic/show?id=72784e6449c' target=_blank style='color:#2F92EE;'>#局部过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47644, encryptionId=72784e6449c, topicName=局部过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Dec 17 14:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047060, encodeId=c2a9204e06031, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 18 08:21:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250594, encodeId=9f241250594b5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405883, encodeId=cdb5140588398, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jan 03 04:21:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356914, encodeId=4d863569144f, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue Jan 01 15:53:07 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2019-01-01 1dd8a7c5m95(暂无匿称)

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

相关资讯

Environ Int:中国儿童喘息和鼻炎的发病和缓解研究

在中国,很少有纵向研究关于儿童室内和室外空气污染接触和相关呼吸道疾病。最近,有研究人员在中国儿童中研究了室内和室外环境与喘息和鼻炎之间的相关性。研究包括了3-6岁的儿童,并随机来自于6个城市。研究人员通过一个父母调查问卷来对喘息、鼻炎和家庭环境数据进行评估,并利用出生后前2年和跟踪调查的最后1年的流行度来计算发病和缓解情况。研究人员发现,产前NO2与喘息缓解的减少和鼻炎流行度的增加和发病的增加相关

Clin Exp Dermatol:在患有过敏性皮肤炎的中国患者中,芳香烃受体多样性与皮肤干燥相关

表皮屏障功能障碍是过敏性皮肤炎(AD)发展的一个起始事件。最近的研究鉴定了芳香烃受体(AHR)在控制丝聚合蛋白基因表达和其他皮肤屏障蛋白中的关键角色,表明了AHR与AD发病机理之间潜在的相关性。最近,有研究人员调查了AHR基因多样性在AD敏感性和AD相关表型中的作用。研究包括了487名患有AD的患者,210名患有牛皮癣的患者和226名健康对照。研究发现,AHR rs10249788和rs20668

Asian Pac J Allergy Immunol:自备的高渗盐水鼻腔冲洗对过敏性鼻炎的效果研究

鼻腔高渗盐水冲洗已经被报道是过敏性鼻炎(AR)辅助治疗的有效方法,但是关于副作用事件、供给为问题以及高昂的花费的考虑限制了其广泛的临床使用。由患者自备的用饮用水制成的1.8%氯化钠生理盐水溶液鼻腔冲洗(SPHNSI)能够解决部分的问题,但是它的临床效果和安全性还需要进一步调查。最近,有研究人员比较了1.8%SPHNSI和0.9%的商业等渗鼻盐水冲洗(0.9%CINSI)在AR患者中治疗的效果和安全

盘点:鼻炎机理盘点

【1】Eur Arch Otorhinolaryngol: 过敏性鼻炎对鼻粘膜重建的不同影响研究过敏性鼻炎(AR)已经报道与慢性鼻窦炎(CRS)相关。最近,有研究人员调查了AR对CRS鼻粘膜重建的影响。研究人员将募集的患者分成不同的小组:具有鼻息肉(NP)和过敏性鼻炎(AR)的CRS患者(CRSwNPwAR,n=20)、具有NP,不具有AR的CRS患者(CRSwNPsAR; n=20)、不具有

Sci Total Environ:周围空气污染接触与年轻儿童呼吸道健康相关性分析

在发展中国家,空气污染对健康的影响越来越受关注。其中儿童就代表了一个群体,他们处在空气污染相关的呼吸道疾病风险增加情况中。最近,有研究人员调查了周围空气污染接触与学校儿童呼吸道健康的关系。研究包括了2532名小学3年级到5年级的来自2个不同学校的学生,时间为2014年到2016年,地点为济南,并且2个学校的空气污染水平不同。周围环境污染水平通过PM10, PM2.5, NO2, SO2, CO和O

盘点:鼻疾病盘点

【1】Otolaryngol Head Neck Surg:鼻窦球囊扩张术后,二次手术相关因素研究尽管鼻窦球囊扩张术(BSP)越来越流行,关于哪位患者是最好的候选人方面了解很少。最近,有研究人员调查了与BSP失败可能相关的因素。研究总共包括了154名患者(平均年龄为53岁):146名患者在单一的医疗系统中经历了BSP;16名(11%)患者在BSP后经历了修正性内镜鼻窦手术(rESS),并在一个